DGX — Quest Diagnostics Share Price
Last trade - 00:00- $19.40bn
- $25.18bn
- $9.87bn
- 91
- 48
- 94
- 92
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.45 | ||
| PEG Ratio (f) | 1.28 | ||
| EPS Growth (f) | 15.85% | ||
| Dividend Yield (f) | 1.76% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.8 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 18.37 | ||
| Price to Sales | 1.91 | ||
| EV to EBITDA | 13.19 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.7% | ||
| Return on Equity | 13.35% | ||
| Operating Margin | 13.7% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 9,437 | 10,788 | 9,883 | 9,252 | 9,872 | 10,781.51 | 11,218.51 | 5.02% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +68.77 | +44.61 | -47.03 | -8.15 | +2.4 | +19.87 | +8.67 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. It also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
Directors
- Stephen Rusckowski CHM (64)
- James Davis CEO (59)
- Mark Guinan CFO (60)
- Michael Prevoznik SVP (59)
- Catherine Doherty SVP (58)
- Carrie Manner SVP (46)
- Timothy Ring LED (64)
- Tracey Doi IND
- Vicky Gregg IND (66)
- Wright Lassiter IND (57)
- Timothy Main IND (63)
- Denise Morrison IND (67)
- Gary Pfeiffer IND (71)
- Helen Torley IND (58)
- Gail Wilensky IND (77)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- September 20th, 1996
- Public Since
- December 17th, 1996
- No. of Shareholders
- 1,991
- No. of Employees
- 45,000
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 111,635,472
- Address
- 500 Plaza Drive, SECAUCUS, 07094
- Web
- https://www.questdiagnostics.com/
- Phone
- +1 9735202700
- Contact
- Shawn Bevec
- Auditors
- PricewaterhouseCoopers LLP
Latest News for DGX
Upcoming Events for DGX
Quest Diagnostics Inc Annual Shareholders Meeting
Quest Diagnostics Inc Annual Shareholders Meeting
Q2 2025 Quest Diagnostics Inc Earnings Release
Q3 2025 Quest Diagnostics Inc Earnings Release
Similar to DGX
Agilon Health
New York Stock Exchange
AMERICAN WELL
New York Stock Exchange
AMN Healthcare Services
New York Stock Exchange
Ardent Health Partners
New York Stock Exchange
Auna SA
New York Stock Exchange
FAQ
As of Today at 22:49 UTC, shares in Quest Diagnostics are trading at $173.76. This share price information is delayed by 15 minutes.
Shares in Quest Diagnostics last closed at $173.76 and the price had moved by +28.31% over the past 365 days. In terms of relative price strength the Quest Diagnostics share price has outperformed the S&P500 Index by +18.44% over the past year.
The overall consensus recommendation for Quest Diagnostics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Quest Diagnostics dividend yield is 1.73% based on the trailing twelve month period.
Last year, Quest Diagnostics paid a total dividend of $3.00, and it currently has a trailing dividend yield of 1.73%. We do not have any data on when Quest Diagnostics is to next pay dividends.
We do not have data on when Quest Diagnostics is to next pay dividends. The historic dividend yield on Quest Diagnostics shares is currently 1.73%.
To buy shares in Quest Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $173.76, shares in Quest Diagnostics had a market capitalisation of $19.40bn.
Here are the trading details for Quest Diagnostics:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: DGX
Based on an overall assessment of its quality, value and momentum Quest Diagnostics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Quest Diagnostics is $183.59. That is 5.66% above the last closing price of $173.76.
Analysts covering Quest Diagnostics currently have a consensus Earnings Per Share (EPS) forecast of $9.69 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Quest Diagnostics. Over the past six months, its share price has outperformed the S&P500 Index by +18.13%.
As of the last closing price of $173.76, shares in Quest Diagnostics were trading +10.16% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Quest Diagnostics PE ratio based on its reported earnings over the past 12 months is 17.45. The shares last closed at $173.76.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Quest Diagnostics' management team is headed by:
- Stephen Rusckowski - CHM
- James Davis - CEO
- Mark Guinan - CFO
- Michael Prevoznik - SVP
- Catherine Doherty - SVP
- Carrie Manner - SVP
- Timothy Ring - LED
- Tracey Doi - IND
- Vicky Gregg - IND
- Wright Lassiter - IND
- Timothy Main - IND
- Denise Morrison - IND
- Gary Pfeiffer - IND
- Helen Torley - IND
- Gail Wilensky - IND